Nicolas Ferreyro reflects on a study about CMS decision to limit the delivery of oral cancer medications
Nicolas Ferreyros, Managing Director at Community Oncology Alliance, posted on LinkedIn:
“A new study presented last week finds that the recent CMS decision to limit the delivery of oral cancer medications “imposes a substantial burden” on patients, particularly those living in socioeconomically disadvantaged neighborhoods.
Key quote: “The removal of flexibilities related to home prescription delivery is anticipated to impose a substantial burden on Texas-based patients by compelling many individuals to undertake long journeys to obtain essential cancer medications.”
The study was presented at ASCO Quality Care Symposium last week. It identified a total of 970 patients who received home-delivered prescriptions under traditional Medicare Part D.
– Of these patients, 71% (687) resided within a 20-mile radius of the nearest clinic, while 22% (213) lived between 20 and 50 miles away.
– Furthermore, 7% (70) of patients lived more than 50 miles from the closest clinic, and 60 addresses could not be properly matched to the [area deprivation index] ADI database [which is a measure of a neighborhoods by socioeconomic disadvantage].
– When considering the ADI rankings, 40% of patients living within 20 miles of the clinic faced significant risks of disparity, a figure that rose to 67% for those residing 20-50 miles away and 61% for individuals living more than 50 miles from the clinic.
Kudos to Lalan Wilfong, Wendy Hemmen, Neal Dave, Erica Feinberg, Gury Doshi with Texas Oncology, The US Oncology Network for the important and extremely timely research.”
For the article click here.
Source: Nicolas Ferreyros/LinkedIn
-
12:46 30/11/23 | BlogJohanna Joyce: the Flashlight method
-
12:31 30/11/23 | InsightJeff Ryckman: Omitting RT in bulky early-stage cHL
-
07:45 30/11/23 | BlogAaron Goodman: Hemoglobin Dissociation Curve! Good stuff
-
12:31 30/11Jeff Ryckman: Omitting RT in bulky early-stage cHL
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows